In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Immunome Inc (NASDAQ: IMNM) closed at $15.48 in the last session, down -9.90% from day before closing price of $17.18. In other words, the price has decreased by -$9.90 from its previous closing price. On the day, 2.1 million shares were traded. IMNM stock price reached its highest trading level at $17.6 during the session, while it also had its lowest trading level at $15.42.
Ratios:
We take a closer look at IMNM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.63 and its Current Ratio is at 6.63. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on April 15, 2024, initiated with a Buy rating and assigned the stock a target price of $35.
On January 29, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $30.
On December 19, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $12.Wedbush initiated its Outperform rating on December 19, 2023, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 02 ’23 when SIEGALL CLAY B bought 169,204 shares for $5.91 per share. The transaction valued at 999,996 led to the insider holds 319,636 shares of the business.
Turner Bruce bought 42,300 shares of IMNM for $249,993 on Oct 02 ’23. The Chief Strategy Officer now owns 42,300 shares after completing the transaction at $5.91 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 924066176 and an Enterprise Value of 783565888. For the stock, the TTM Price-to-Sale (P/S) ratio is 65.91 while its Price-to-Book (P/B) ratio in mrq is 5.58. Its current Enterprise Value per Revenue stands at 55.897 whereas that against EBITDA is -27.716.
Stock Price History:
Over the past 52 weeks, IMNM has reached a high of $30.96, while it has fallen to a 52-week low of $4.44. The 50-Day Moving Average of the stock is -32.66%, while the 200-Day Moving Average is calculated to be 24.02%.
Shares Statistics:
According to the various share statistics, IMNM traded on average about 750.63K shares per day over the past 3-months and 787030 shares per day over the past 10 days. A total of 59.69M shares are outstanding, with a floating share count of 48.31M. Insiders hold about 19.07% of the company’s shares, while institutions hold 35.83% stake in the company. Shares short for IMNM as of 1711584000 were 3240838 with a Short Ratio of 4.32, compared to 1709164800 on 2650324. Therefore, it implies a Short% of Shares Outstanding of 3240838 and a Short% of Float of 5.57.
Earnings Estimates
The stock of Immunome Inc (IMNM) is currently drawing attention from MNM analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $1.17, with high estimates of $0.44 and low estimates of $15.48.
